Breaking News Instant updates and real-time market news.

AVEO

Aveo Pharmaceuticals

$2.00

0.005 (0.25%)

07:03
11/09/18
11/09
07:03
11/09/18
07:03

Aveo Pharmaceuticals reports Q3 EPS (18c), consensus (6c)

Reports Q3 revenue $2.5M, may not compare to consensus $680,000.

  • 27

    Nov

AVEO Aveo Pharmaceuticals
$2.00

0.005 (0.25%)

10/22/18
PIPR
10/22/18
NO CHANGE
Target $5
PIPR
Overweight
TiNivo data competitively position Aveo Pharmaceuticals, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes the data for tivozanib combined with Opdivo to treat metastatic renal cell carcinoma presented at the ESMO meeting competitively position Aveo Pharmaceuticals as the treatment landscape for front-line RCC moves to I-O and TKI combinations. An ORR of 56% and DCR of 96% represent "promising early activity," said Tenthoff., who reiterates his Overweight rating and $5 target on Aveo shares.
11/05/18
PIPR
11/05/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Pharmaceuticals tivozanib's initial sales seen at $27M, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $5 price target on Aveo Pharmaceuticals after its announcement this evening that the phase 3 TIVO-3 trial of tivozanib vs. Nexavar in 3rd line renal cell carcinoma met its primary endpoint target. The analyst expects the company to file a New Drug Application for tivozanib in the next 6 months, and after its expected approval, he estimates that the initial 2020 sales will be around $27M before reaching about $189M in 2025. Tenthoff adds that based on the data, there is further opportunity for tivozanib use in compbination with Opdivo.
11/06/18
HCWC
11/06/18
NO CHANGE
Target $9
HCWC
Buy
Aveo Pharmaceuticals price target raised to $9 from $6.50 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Aveo Pharmaceuticals to $9 saying the company announced positive topline results from the Phase 3 TIVO-3 study investigating the use of tivozanib for the treatment of refractory renal cell carcinoma. The analyst views the results as "very promising" and believes tivozanib still has "ample opportunity" to show a superior overall survival benefit. He believes the drug is on track for approval in 2020 and keeps a Buy rating on Aveo Pharmaceuticals.
11/06/18
NATL
11/06/18
DOWNGRADE
NATL
Neutral
Aveo Pharmaceuticals downgraded to Neutral from Buy at National Securities

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.